

## SACRAL NEUROMODULATION: LONG-TERM EFFICACY, INCIDENCE AND PREDICTORS OF COMPLICATIONS

### Hypothesis / aims of study

The aim of this paper is to examine the long-term efficacy and durability of sacral nerve stimulation (SNS), report the complications in a large series of patients and to identify predictors of complications / failures in order to optimize patient selection and outcomes.

### Study design, materials and methods

A retrospective review was performed to determine the incidence and predictors of complications with SNS. Patients with refractory urgency incontinence, urgency/frequency or idiopathic urinary retention treated with SNS were identified and selected as the study cohort. Patients completed a one-week voiding log and underwent urodynamic evaluation prior to staged SNS lead placement with the Interstim® (Medtronic) device. Patients were followed for evidence of complications and device efficacy. Patients and device variables including operative indications, patients co-morbidities and social history, as well as the type of lead and generator employed were examined statistically for evidence of predictive value.

### Results

From June 2001 to March 2008 271 patients (228 females and 43 males) with an average age of 52 years (range 17-86 years) underwent staged SNS lead placement by a single surgeon, for intractable urgency incontinence (126), urgency/frequency (105) or idiopathic urinary retention (40). Of this group 244 patients (90%) experienced a greater than 50% improvement in symptoms based on a one-week voiding log and underwent IPG placement. At mean follow-up of 38 months (range 2-80 months) complications were identified in 62 patients (25%). 45 patients (18%) required either lead revision, IPG revision or both secondary to lead migration or trauma; 3 patients (1%) developed haematoma at the IPG site requiring explanation or drainage; and a total of 39 patients (16%) have had their device explanted. Of these 13 (5%) were for infections, 5 (2%) were because the patient required an MRI exam, 1 was for intractable diarrhea and 20 (8%) were for lack of durable efficacy or because the patient wanted it removed. When analyzed statistically patients who were wheelchair bound had a body mass index (BMI) <18 or >30, and/or had a past history of recurrent trauma were significantly more likely to experience device complications or failures ( $p < 0.5$ ). There was a trend towards revisions and complications among public aid recipients and patients treated in a pain clinic ( $p = 0.071, 0.063$ ). Use of a non-tined lead was a predictor for device revision ( $p < 0.05$ ). Likewise complications and revision rates for the IPG II were rare. Overall, 207 patients (85%) presently have functioning Interstim® device.

### Interpretation of results

SNS is an effective treatment for patients with intractable voiding dysfunction. Complications are not uncommon but can be minimized.

### Concluding message

Complications may be minimized with better patient selection, use of the IPG II, an experienced surgeon and a dedicated clinical programmer. A committed and educated patient may ultimately represent the most important key to success.

<b><i>Specify source of funding or grant</i></b>	<b>None</b>
<b><i>Is this a clinical trial?</i></b>	<b>No</b>
<b><i>What were the subjects in the study?</i></b>	<b>HUMAN</b>
<b><i>Was this study approved by an ethics committee?</i></b>	<b>No</b>
<b><i>This study did not require ethics committee approval because</i></b>	<b>this is a retrospective review of patients treated with SNS for their voiding dysfunction</b>
<b><i>Was the Declaration of Helsinki followed?</i></b>	<b>Yes</b>
<b><i>Was informed consent obtained from the patients?</i></b>	<b>Yes</b>